Lamellar Ichthyosis (LI) is a type of autosomal recessive congenital Ichthyosis (ARCI), which is a clinically and genetically heterogeneous group of dermatological scaly skin disorders. Infants affected with LI are born encased in a hyperkeratotic translucent membrane, known as collodion baby, and within 2 weeks develop large, thick, brownish lamellar scales with minimal erythema. Additionally, LI is associated with crumpled ears, alopecia, eclabium, and ectropion. Lamellar Ichthyosis is treated topically with skin barrier repair formulas containing ceramides or cholesterol, moisturizers with petrolatum or lanolin, and mild keratolytics (products containing alpha-hydroxy acids or urea).
Visit For Sample Pages:
https://www.delveinsight.com/sample-request/lamellar-ichthyosis-market
The Lamellar Ichthyosis market report aslo covers emerging drugs, current treatment practices, Lamellar Ichthyosis market share of the individual therapies, current and forecasted Lamellar Ichthyosis Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Lamellar Ichthyosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Lamellar Ichthyosis Market Key Facts
-
Lamellar Ichthyosis is estimated to affect 1 in 100,000 individuals in the United States. This condition is more common in Norway, where an estimated range is 1 in 91,000 individuals. As per the British Association of Dermatologists, Lamellar Ichthyosis is a rare form occurring in 1 in 200,000 live births in the United Kingdom.
-
Total Prevalence of Inherited Ichthyosis in France was estimated at 13.3 per million people and the prevalence of lamellar Ichthyosis was 4.5 per million people.
-
In a study conducted in Japan with 220 patients treated for ARCI and Ichthyosis syndromes, 95 patients were observed with Nonbullous Congenital Ichthyosiform erythroderma, 30 with lamellar Ichthyosis, and 15 with harlequin Ichthyosis (Kurosawa et al.)
-
A study conducted in Spain on 144 patients with ARCI has shown that among these patients, 62.5% had classic Lamellar Ichthyosis and 30.6% had congenital Ichthyosiform Erythroderma (Martín et al).
Key Benefits of Lamellar Ichthyosis Market Report
-
Lamellar Ichthyosis market report provides an in-depth analysis of Lamellar Ichthyosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
-
The Lamellar Ichthyosis market report will help in developing business strategies by understanding the Lamellar Ichthyosis Market trends & developments, key players and future market competition that will shape and drive the Lamellar Ichthyosis market in the upcoming years.
-
The Lamellar Ichthyosis market report covers Lamellar Ichthyosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
-
The report provides a detailed assessment of the Lamellar Ichthyosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population, comparative analysis of pipeline products with detailed clinical profiles, and other factors.
The Lamellar Ichthyosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Lamellar Ichthyosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology.
The report gives a thorough detail of Lamellar Ichthyosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders.
Lamellar Ichthyosis Epidemiology
The Lamellar Ichthyosis epidemiology section covers insights about historical and current Lamellar Ichthyosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.
It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Lamellar Ichthyosis Drugs Uptake and Key Market Players
The Lamellar Ichthyosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Lamellar Ichthyosis market or expected to get launched in the market during the study period. The analysis covers Lamellar Ichthyosis market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of Lamellar Ichthyosis (LI) market is expected to change due to the improvement in the diagnosis, incremental healthcare expenditure across the world and expected launch of emerging therapies during the forecast period of 2019─2030. Companies all over the globe are persistently working towards the development of new treatment therapies and some of the key players at the global level are Mayne Pharma, Krystal Biotech, Timber Pharmaceuticals, and others.
Table of Content
1. Key Insights
2. Executive Summary
3. Lamellar Ichthyosis Competitive Intelligence Analysis
4. Lamellar Ichthyosis Market Overview at a Glance
5. Lamellar Ichthyosis Disease Background and Overview
6. Lamellar Ichthyosis Patient Journey
7. Lamellar Ichthyosis Epidemiology and Patient Population
8. Lamellar Ichthyosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Lamellar Ichthyosis Unmet Needs
10. Key Endpoints of Lamellar Ichthyosis Treatment
11. Lamellar Ichthyosis Marketed Products
12. Lamellar Ichthyosis Emerging Therapies
13. Lamellar Ichthyosis Seven Major Market Analysis
14. Attribute Analysis
15. Lamellar Ichthyosis Market Outlook (7 major markets)
16. Lamellar Ichthyosis Access and Reimbursement Overview
17. KOL Views on the Lamellar Ichthyosis Market.
18. Lamellar Ichthyosis Market Drivers
19. Lamellar Ichthyosis Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Related Reports-
Lamellar Ichthyosis (LI) Epidemiology Forecast to 2030
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/